Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).

The receptor activator of nuclear factor‑κB ligand (RANKL)/RANK/osteoprotegerin (OPG) system was identified in the late 1990s, ending the search for the specific factors expressed by osteoblasts and stromal cells in order to regulate osteoclastogenesis. The identification of the RANKL/RANK/OPG system was a breakthrough in bone biology; however, the system not only works as a dominant mediator in osteoclast activation, formation and survival, but also functions in other tissues, including the mammary glands, brain and lymph nodes. Evidence has indicated that the existence of the RANKL/RANK/OPG system in these tissues suggests that it may have specific functions beyond those in bone. Disorders of the RANKL/RANK/OPG system are associated with certain human diseases, including postmenopausal osteoporosis, rheumatoid arthritis (RA), bone tumors and certain bone metastatic tumors. Genetic studies have indicated that the RANKL/RANK/OPG system may be a key regulator in the formation of lymph nodes and in the autoimmune disease RA, which further suggests that the immune system may interact with the RANKL/RANK/OPG system. The present review aimed to provide an overview of the role of the RANKL/RANK/OPG system in osteoclastogenesis, bone disease and tissues beyond bone.

[1]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[2]  H. Takayanagi.  New developments in osteoimmunology , 2012, Nature Reviews Rheumatology.

[3]  R. Goeree,et al.  Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada , 2012, Journal of medical economics.

[4]  P. Miller,et al.  Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial , 2012, Osteoporosis International.

[5]  P. Kostenuik,et al.  Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.

[6]  P. Kostenuik,et al.  Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. , 2012, Clinical therapeutics.

[7]  Liza J. Raggatt,et al.  Cellular and Molecular Mechanisms of Bone Remodeling* , 2010, The Journal of Biological Chemistry.

[8]  J. Dungan.  Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis , 2010 .

[9]  H. Takayanagi.  Osteoimmunology and the effects of the immune system on bone , 2009, Nature Reviews Rheumatology.

[10]  A. Haeseler,et al.  Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.

[11]  J. Pelletier,et al.  New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? , 2009, The Keio journal of medicine.

[12]  Malcolm D. Smith,et al.  Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. , 2008, Arthritis and rheumatism.

[13]  L. Xing,et al.  Functions of RANKL/RANK/OPG in bone modeling and remodeling. , 2008, Archives of biochemistry and biophysics.

[14]  P. Kostenuik,et al.  RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Chin-Tong Ong,et al.  NOTCH1 Regulates Osteoclastogenesis Directly in Osteoclast Precursors and Indirectly via Osteoblast Lineage Cells* , 2008, Journal of Biological Chemistry.

[16]  J. Salo,et al.  Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. , 2008, Clinical and experimental rheumatology.

[17]  Rik Huiskes,et al.  A unified theory for osteonal and hemi-osteonal remodeling. , 2008, Bone.

[18]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications , 2007 .

[19]  N. Bishop,et al.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.

[20]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[21]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[22]  J. Caetano-Lopes,et al.  Osteoblasts and bone formation. , 2007, Acta reumatologica portuguesa.

[23]  H. Takayanagi.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.

[24]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-B ( RANK ) / RANK Ligand / Osteoprotegerin : Clinical Implications , 2007 .

[25]  W. Dougall,et al.  The RANK/RANKL/OPG triad in cancer-induced bone diseases , 2007, Cancer and Metastasis Reviews.

[26]  S. Goldring,et al.  RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. , 2006, Rheumatology.

[27]  P. Delmas,et al.  Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.

[28]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[29]  G. Rodan,et al.  Role of osteoblasts in hormonal control of bone resorption—A hypothesis , 2006, Calcified Tissue International.

[30]  L. Raisz.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects. , 2005, The Journal of clinical investigation.

[31]  Tak W. Mak,et al.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.

[32]  T. Kodama,et al.  NFAT and Osterix cooperatively regulate bone formation , 2005, Nature Medicine.

[33]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[34]  J. Penninger,et al.  The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis , 2005, Nature Medicine.

[35]  S. Takeshita,et al.  Functional Identification of Three Receptor Activator of NF-κB Cytoplasmic Motifs Mediating Osteoclast Differentiation and Function* , 2004, Journal of Biological Chemistry.

[36]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[37]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[38]  R. Kitazawa,et al.  Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. , 2003, The Journal of biological chemistry.

[39]  William Shakespeare,et al.  Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. , 2003, Kidney international. Supplement.

[40]  P. Tak,et al.  Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. , 2003, Rheumatology.

[41]  R. Bataille,et al.  Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. , 2002, Blood.

[42]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[43]  L. Hofbauer,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[44]  I. Reid,et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.

[45]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[46]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[47]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[48]  E. Wagner,et al.  Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.

[49]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[50]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[51]  Steffen Jung,et al.  Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance , 2000, The Journal of experimental medicine.

[52]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[53]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[55]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[56]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[57]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[58]  Y. Bi,et al.  Regulation of osteoclast activity. , 1999, Life sciences.

[59]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[60]  Sakae Tanaka,et al.  Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[61]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.

[62]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[63]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Kwon,et al.  Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinase , 1999, FEBS letters.

[65]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[66]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[67]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[68]  B. Aggarwal,et al.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.

[69]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[70]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[72]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[73]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[74]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[75]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[76]  Ghannam Nn.  Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994 .

[77]  N. Ghannam,et al.  Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.